QIAGEN Receives the US FDA Clearance for QIAstat-Dx BCID GN Plus AMR Panel

Shots: The US FDA has granted clearance to the QIAstat-Dx BCID GN Plus AMR Panel, completing QIAGEN’s US bloodstream infection testing portfolio with coverage of gram-negative bacteria & antimicrobial resistance markers The new panel can detect 13 gram-negative bacterial targets & 18 AMR markers from positive blood cultures in about one hour, complementing the previously cleared QIAstat-Dx BCID GPF Plus AMR Panel for gram-positive bacteria and fungi Together, the two QIAstat-Dx panels cover 33 pathogen targets and 28 AMR markers, providing US laboratories with rapid molecular information to support treatment decisions, antimicrobial stewardship, & infection control Ref: Businesswire   |   Image:  QIAGEN  |  Press Release PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com The post QIAGEN Receives the US FDA Clearance for QIAstat-Dx BCID GN Plus AMR Panel appeared first on PharmaShots.